Board of Pharmacy Dr. Allison Hill Confirmation Resolution of 2026
Summary
This resolution confirms the Mayor’s reappointment of Dr. Allison Hill as the pharmacist licensed in the District member of the District of Columbia Board of Pharmacy. The appointment is for a term ending March 12, 2028. The resolution also directs that copies be transmitted to the nominee and the Mayor after adoption and takes effect immediately.
The bill is a personnel/confirmation measure rather than a policy change. It operates under the District’s Confirmation Act of 1978 and the Health Occupations Revision Act of 1985, specifically the statutory provision establishing the Board of Pharmacy. By confirming Dr. Hill, the Council would continue her service on the board that oversees pharmacy practice and related professional regulation in the District.
Impact
If adopted, the resolution would not amend substantive pharmacy law, but it would maintain the composition of the Board of Pharmacy by reappointing an existing licensed pharmacist member. The Board of Pharmacy is the body responsible for oversight of pharmacy practice, licensure-related matters, and professional regulation under D.C. health occupations law, so the practical effect is to preserve continuity in board governance and regulatory administration.
Sentiment
The available materials suggest a routine and favorable confirmation process. The Mayor formally requested the Council’s earliest consideration, the nominee’s qualifications were presented in detail, and the Office of the General Counsel reviewed the resolution and found it legally unobjectionable. No votes, hearings, or committee transcripts are included showing opposition or debate, which indicates the nomination appears to have been treated as noncontroversial.
Contention
No specific points of contention are evident in the provided record. Because there are no committee transcripts or recorded votes, there is no documented disagreement over Dr. Hill’s qualifications, the board’s composition, or the underlying appointment authority. Any potential issue would likely be limited to the standard confirmation review process rather than a substantive policy dispute.